Welcome to our dedicated page for VISKASE HOLDINGS SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viskase Holdings, Inc. (ENZN) filings document the issuer's completed transition from Enzon Pharmaceuticals, Inc. to Viskase Holdings, including material-event reports on the merger closing, name change, exchange offer for Series C Non-Convertible Redeemable Preferred Stock, and related capital-structure disclosures.
The company's 8-K records also cover governance and ownership matters, including a Section 382 Rights Agreement, changes in certifying accountant, officer appointments, and amendments to the credit agreement of Viskase Companies, LLC, a wholly owned subsidiary. Other recurring disclosure areas include shareholder voting matters, material agreements, operating and financial results, risk factors, and legacy clinical or regulatory disclosures.
Enzon Pharmaceuticals, Inc. reported that it entered into a Tenth Amendment to its Section 382 Rights Agreement, extending the Final Expiration Date of the rights from noon, New York City time, on March 18, 2026 to noon, New York City time, on March 24, 2026.
Management states that this new March 24, 2026 expiration is believed to be in the best interests of the company and its stockholders. Apart from the new Final Expiration Date, all other terms of the Rights Agreement remain unchanged.
Enzon Pharmaceuticals announced an extension of its exchange offer for holders of Series C Non-Convertible Redeemable Preferred Stock to exchange into Enzon common stock; the Offer now expires at 5:00 p.m. Eastern on March 19, 2026, unless further extended.
The filing also reiterates that Enzon filed a Form S-4 registration statement in connection with the proposed merger with Viskase Companies, Inc., which contains a prospectus, consent solicitation statement and offer to exchange; the Registration Statement and related documents are available on the SEC website and Enzon’s website.
Enzon Pharmaceuticals reported that it has extended the expiration date of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock, who are being offered Enzon common stock in exchange for their preferred shares. The offer now expires at 5:00 p.m. Eastern time on March 19, 2026, unless further extended.
This exchange offer is part of a broader proposed transaction between Enzon and Viskase Companies, Inc., for which Enzon has filed a Form S-4 registration statement containing a combined prospectus, consent solicitation statement and offer to exchange. The filing also reiterates extensive forward-looking risk factors that could affect completion and outcomes of the proposed merger and the combined company.
Enzon Pharmaceuticals amended its Schedule TO to report results and extend its exchange Offer for Series C Non-Convertible Redeemable Preferred Stock. The Offer exchanges each share of Series C Preferred Stock for Common Stock using the liquidation preference divided by $7.83 after the Reverse Stock Split.
Enzon extended the Offer expiration to 5:00 p.m. Eastern Time on March 19, 2026. The Depositary reported that as of 5:00 p.m. ET on March 13, 2026, 342 shares had been validly tendered and not withdrawn, representing less than 1% of 40,000 shares outstanding.
Enzon Pharmaceuticals, Inc. amended its Section 382 Rights Agreement for the ninth time to push the Final Expiration Date to noon, New York City time, on March 18, 2026. The Rights Agreement is otherwise unchanged and the filing recites prior amendments that moved the expiration repeatedly.
The company also issued a press release stating the exchange offer for Series C Preferred Stock now expires at 5:00 p.m., Eastern time, on March 16, 2026, unless further extended. The filing incorporates the Ninth Amendment as Exhibit 4.1 and the press release as Exhibit 99.1.
Enzon Pharmaceuticals, Inc. entered into a Ninth Amendment to its Section 382 Rights Agreement, moving the rights’ Final Expiration Date from noon, New York City time, on March 11, 2026, to noon, New York City time, on March 18, 2026. Management states this extension is in the best interests of the company and its stockholders, and all other terms of the rights plan remain unchanged. The company also announced that its exchange offer to swap Series C Non-Convertible Redeemable Preferred Stock for Enzon common stock has been extended to 5:00 p.m. Eastern time on March 16, 2026, unless further extended. The filing also reminds investors that Enzon has filed a Form S-4 registration statement for its proposed merger with Viskase Companies, Inc., which contains detailed information about the combined company.
Enzon Pharmaceuticals amended its Schedule TO to report results and extend its exchange Offer for Series C Non-Convertible Redeemable Preferred Stock. The Company extended the Offer deadline to 5:00 p.m. Eastern Time on March 16, 2026. As of 5:00 p.m. ET on March 10, 2026, 340 shares had been validly tendered and not withdrawn, representing less than 1% of the 40,000 shares outstanding as of that date. Previously scheduled expiration was one minute after 11:59 p.m. ET on March 11, 2026. Holders who already validly tendered need not re-tender.
Enzon Pharmaceuticals announced an extension of its exchange offer to permit holders of its Series C Non-Convertible Redeemable Preferred Stock to exchange those shares for Enzon common stock. After the extension, the Offer expires one minute after 11:59 p.m., Eastern time, on March 11, 2026, unless the Offer is further extended.
The filing also reminds readers that Enzon filed a Form S-4 registration statement in connection with the proposed merger with Viskase Companies, Inc. and that the Registration Statement and related materials, including financial information for the combined company, are available on www.sec.gov and on Enzon’s website.
Enzon Pharmaceuticals, Inc. announced that it has extended the expiration date of its exchange offer to holders of its Series C Non-Convertible Redeemable Preferred Stock, who may exchange those shares for Enzon common stock. The offer now expires one minute after 11:59 p.m., Eastern time, on March 11, 2026, unless further extended.
The update sits alongside disclosures about Enzon’s proposed merger with Viskase Companies, Inc. and references a previously filed Form S-4 registration statement that includes a prospectus, consent solicitation statement and offer to exchange, as well as detailed risk factors and forward-looking statement warnings for the combined company.
Enzon Pharmaceuticals extended its exchange Offer for Series C Non-Convertible Redeemable Preferred Stock to one minute after 11:59 p.m., Eastern Time, on March 11, 2026. As of 5:00 p.m. ET on March 6, 2026, 339 shares had been validly tendered and not withdrawn, representing less than 1% of the 40,000 shares outstanding as of March 6, 2026.
The Offer exchanges each Series C preferred share for Common Stock at a ratio equal to the share's aggregate liquidation preference divided by $7.83, after giving effect to the Reverse Stock Split; prior terms and conditions remain unchanged.